Kalshi, a predictive markets platform, saw US visits surge 1,520% to 15.4 million in July 2026, with trading volume hitting $40 billion monthly. Despite ongoing legal challenges over whether its sports contracts fall under federal or state law, Kalshi has launched leveraged crypto perpetual contracts on BTC, ETH, BNB, and 14 other assets with up to 6x leverage. This move expands its offerings but complicates its regulatory situation as it faces scrutiny from both the Supreme Court and the Commodity Futures Trading Commission (CFTC). The platform's rapid growth and new crypto products highlight a regulatory battle between state gambling laws and federal derivatives oversight.
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
